vs
LGI Homes, Inc.（LGIH）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是LGI Homes, Inc.的1.3倍（$622.0M vs $474.0M），Royalty Pharma plc净利率更高（34.4% vs 3.7%，领先30.8%），Royalty Pharma plc同比增速更快（4.8% vs -15.0%），过去两年LGI Homes, Inc.的营收复合增速更高（10.1% vs 4.6%）
LGI Homes是一家总部位于美国得克萨斯州的新建住宅开发商，业务聚焦美国西南部地区。据《建筑商》杂志统计，该公司目前是美国第十大住宅建筑商，2019年共交付房屋7690套，较2018年增长18.1%，全年房屋销售营收达18亿美元，行业规模位居美国前列。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
LGIH vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.3倍
$474.0M
营收增速更快
RPRX
高出19.7%
-15.0%
净利率更高
RPRX
高出30.8%
3.7%
两年增速更快
LGIH
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $474.0M | $622.0M |
| 净利润 | $17.3M | $214.2M |
| 毛利率 | 17.7% | — |
| 营业利润率 | 3.9% | 62.4% |
| 净利率 | 3.7% | 34.4% |
| 营收同比 | -15.0% | 4.8% |
| 净利润同比 | -66.0% | 2.9% |
| 每股收益（稀释后） | $0.74 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LGIHRPRX
| Q4 25 | $474.0M | $622.0M | ||
| Q3 25 | $396.6M | $609.3M | ||
| Q2 25 | $483.5M | $578.7M | ||
| Q1 25 | $351.4M | $568.2M | ||
| Q4 24 | $557.4M | $593.6M | ||
| Q3 24 | $651.9M | $564.7M | ||
| Q2 24 | $602.5M | $537.3M | ||
| Q1 24 | $390.9M | $568.0M |
净利润LGIHRPRX
| Q4 25 | $17.3M | $214.2M | ||
| Q3 25 | $19.7M | $288.2M | ||
| Q2 25 | $31.5M | $30.2M | ||
| Q1 25 | $4.0M | $238.3M | ||
| Q4 24 | $50.9M | $208.2M | ||
| Q3 24 | $69.6M | $544.0M | ||
| Q2 24 | $58.6M | $102.0M | ||
| Q1 24 | $17.1M | $4.8M |
毛利率LGIHRPRX
| Q4 25 | 17.7% | — | ||
| Q3 25 | 21.5% | — | ||
| Q2 25 | 22.9% | — | ||
| Q1 25 | 21.0% | — | ||
| Q4 24 | 22.9% | — | ||
| Q3 24 | 25.1% | — | ||
| Q2 24 | 25.0% | — | ||
| Q1 24 | 23.4% | — |
营业利润率LGIHRPRX
| Q4 25 | 3.9% | 62.4% | ||
| Q3 25 | 5.4% | 70.1% | ||
| Q2 25 | 8.2% | 36.3% | ||
| Q1 25 | 0.0% | 94.0% | ||
| Q4 24 | 8.2% | 60.9% | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | 11.2% | 50.2% | ||
| Q1 24 | 4.8% | -13.0% |
净利率LGIHRPRX
| Q4 25 | 3.7% | 34.4% | ||
| Q3 25 | 5.0% | 47.3% | ||
| Q2 25 | 6.5% | 5.2% | ||
| Q1 25 | 1.1% | 41.9% | ||
| Q4 24 | 9.1% | 35.1% | ||
| Q3 24 | 10.7% | 96.3% | ||
| Q2 24 | 9.7% | 19.0% | ||
| Q1 24 | 4.4% | 0.8% |
每股收益（稀释后）LGIHRPRX
| Q4 25 | $0.74 | $0.49 | ||
| Q3 25 | $0.85 | $0.67 | ||
| Q2 25 | $1.36 | $0.07 | ||
| Q1 25 | $0.17 | $0.55 | ||
| Q4 24 | $2.15 | $0.46 | ||
| Q3 24 | $2.95 | $1.21 | ||
| Q2 24 | $2.48 | $0.23 | ||
| Q1 24 | $0.72 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | $1.7B | $9.0B |
| 股东权益账面价值 | $2.1B | $9.7B |
| 总资产 | $3.9B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.79× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资LGIHRPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $53.2M | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务LGIHRPRX
| Q4 25 | $1.7B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $1.5B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益LGIHRPRX
| Q4 25 | $2.1B | $9.7B | ||
| Q3 25 | $2.1B | $9.6B | ||
| Q2 25 | $2.1B | $9.5B | ||
| Q1 25 | $2.0B | $9.8B | ||
| Q4 24 | $2.0B | $10.3B | ||
| Q3 24 | $2.0B | $10.3B | ||
| Q2 24 | $1.9B | $9.8B | ||
| Q1 24 | $1.9B | $9.9B |
总资产LGIHRPRX
| Q4 25 | $3.9B | $19.6B | ||
| Q3 25 | $4.0B | $19.3B | ||
| Q2 25 | $4.0B | $18.3B | ||
| Q1 25 | $3.9B | $17.6B | ||
| Q4 24 | $3.8B | $18.2B | ||
| Q3 24 | $3.8B | $18.0B | ||
| Q2 24 | $3.7B | $17.7B | ||
| Q1 24 | $3.5B | $16.1B |
负债/权益比LGIHRPRX
| Q4 25 | 0.79× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.73× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $86.8M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 5.01× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流LGIHRPRX
| Q4 25 | $86.8M | $827.1M | ||
| Q3 25 | $-13.2M | $702.6M | ||
| Q2 25 | $-86.4M | $364.0M | ||
| Q1 25 | $-127.1M | $596.1M | ||
| Q4 24 | $57.0M | $742.5M | ||
| Q3 24 | $-17.8M | $703.6M | ||
| Q2 24 | $-83.5M | $658.2M | ||
| Q1 24 | $-99.5M | $664.6M |
自由现金流LGIHRPRX
| Q4 25 | — | — | ||
| Q3 25 | $-13.3M | — | ||
| Q2 25 | $-86.4M | — | ||
| Q1 25 | $-128.0M | — | ||
| Q4 24 | $56.4M | — | ||
| Q3 24 | $-17.8M | — | ||
| Q2 24 | $-83.8M | — | ||
| Q1 24 | $-100.5M | — |
自由现金流率LGIHRPRX
| Q4 25 | — | — | ||
| Q3 25 | -3.3% | — | ||
| Q2 25 | -17.9% | — | ||
| Q1 25 | -36.4% | — | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | -2.7% | — | ||
| Q2 24 | -13.9% | — | ||
| Q1 24 | -25.7% | — |
资本支出强度LGIHRPRX
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.3% | — |
现金转化率LGIHRPRX
| Q4 25 | 5.01× | 3.86× | ||
| Q3 25 | -0.67× | 2.44× | ||
| Q2 25 | -2.74× | 12.06× | ||
| Q1 25 | -31.83× | 2.50× | ||
| Q4 24 | 1.12× | 3.57× | ||
| Q3 24 | -0.26× | 1.29× | ||
| Q2 24 | -1.43× | 6.45× | ||
| Q1 24 | -5.83× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGIH
| West Reportable Segment | $128.2M | 27% |
| Southeast Reportable Segment | $118.9M | 25% |
| Central Reportable Segment | $105.8M | 22% |
| Florida Reportable Segment | $69.2M | 15% |
| Northwest Reportable Segment | $51.8M | 11% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
